Anaptysbio (ANAB) Income from Continuing Operations (2016 - 2026)
Anaptysbio (ANAB) reported Income from Continuing Operations of 52884000.0 for Q1 2026, down 34.47% on a YoY basis from 80696625.9 in Q1 2025, and down 184.37% quarter-over-quarter from 62682000.0 in Q4 2025.
Anaptysbio (ANAB) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Anaptysbio has reported Income from Continuing Operations for 11 years, with the latest figure at 52884000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 34.47% year-over-year to 52884000.0; the trailing twelve-month figure through Mar 2026 stood at 13719000.0 (up 90.25% YoY), and the FY2025 full-year result was 164000.0, up 99.89% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 52884000.0, down from 62682000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 121369000.0 in Q4 2023, with the low at 52884000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 17748294.12 across 5 years, with a median of 32851000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 6121.91% — and 2023, when it soared 648.34%.
- Anaptysbio's Income from Continuing Operations stood at 22134000.0 in 2022, then soared by 648.34% to 121369000.0 in 2023, then tumbled by 118.06% to 21923000.0 in 2024, then surged by 385.92% to 62682000.0 in 2025, then plunged by 184.37% to 52884000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 52884000.0 (Q1 2026), 62682000.0 (Q4 2025), and 15113000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Anaptysbio | 1.66 Bn | 1.38 Bn | - | -52.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.88 Mn |
| Dec 31, 2025 | 62.68 Mn |
| Sep 30, 2025 | 15.11 Mn |
| Jun 30, 2025 | -38.63 Mn |
| Mar 31, 2025 | -39.33 Mn |
| Dec 31, 2024 | -21.92 Mn |
| Sep 30, 2024 | -32.85 Mn |
| Jun 30, 2024 | -46.66 Mn |
| Mar 31, 2024 | -43.94 Mn |
| Dec 31, 2023 | 121.37 Mn |
| Sep 30, 2023 | -37.31 Mn |
| Jun 30, 2023 | -39.85 Mn |
| Mar 31, 2023 | -39.92 Mn |
| Dec 31, 2022 | -22.13 Mn |
| Sep 30, 2022 | -27.37 Mn |
| Jun 30, 2022 | -26.69 Mn |
| Mar 31, 2022 | -31.41 Mn |
| Dec 31, 2021 | -31.09 Mn |
| Sep 30, 2021 | -6.70 Mn |
| Jun 30, 2021 | -429,000.00 |